Directors Declaration

Advanced Medical Solutions Grp PLC
13 April 2007


For Immediate Release                                             13 April 2007



                      Advanced Medical Solutions Group plc

                             ('AMS' or 'the Group')

            Directors purchase of shares and issue of share options



Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, announces today that Don Evans, Chief Executive
Officer; Mary Tavener, Finance Director; and Chris Meredith, Commercial
Director, have today subscribed for 43,859, 43,859, and 30,136 new ordinary
shares respectively as part of the Deferred Share Bonus Plan (the 'Plan'). These
ordinary shares were subscribed at a price of 18.25p per share and, under the
terms of the Plan, will be held in trust on their behalf.



As a result, Don Evans has a beneficial and non beneficial interest in 743,859
ordinary shares, representing 0.52% of the issued share capital of the Company,
Mary Tavener has both a beneficial and non beneficial interest in 155,421
ordinary shares, representing 0.11% of the issued share capital of the Company,
and Chris Meredith has both a beneficial and non beneficial interest in 45,136
ordinary shares, representing 0.03% of the issued share capital of the Company.



In addition, the Board granted 1,136,000 new share options to Don Evans, 866,000
new share options to Mary Tavener and 708,000 new share options to Chris
Meredith under the Advanced Medical Solutions Long Term Incentive Plan (the '
LTIP') on 12 April 2007. As a result, Don Evans now  has an interest in
3,001,173 options under the LTIP scheme and 616,666 options under the Advanced
Medical Solutions Executive Share Option Scheme (the 'Executive Scheme'),
representing 2.5% of the Company's issued  share capital. Mary Tavener now has
an interest in 2,214,571 options under the LTIP scheme and 300,000 options under
the Executive Scheme, representing 1.8% of the Company's issued share capital.
Chris Meredith now has an interest in 1,208,000 options under the LTIP scheme,
representing 0.8% of the Company's issued share capital. The new options will be
priced at the average market price of 16.75p for the three business days prior
to the grant and are subject to performance conditions over a three year period
to vest.



For further information, please contact:


Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer                      Tel: [phone]
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications
Mary-Jane Johnson                                      Tel: [phone]





Notes to Editors:



Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.



Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the
design, development and manufacture of innovative and technologically advanced
products for woundcare and other medical applications.



In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.



The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing topical wounds sold direct to hospitals or through
distributors.



AMS's technology and products currently serve the majority of the key global
markets and strategic partners.


                      This information is provided by RNS
            The company news service from the London Stock Exchange